把供应商、客户、政府合同、重大协议、项目与产能做成逐条可核验的关系账本。 每条边都保留方向、证据等级、原文、日期和官方链接，不把“属于同一产业链”当成真实供销关系。
| 关系方向 | 关系 / 状态 | 金额 / 产能 | 证据 | 披露日期 | 详情 |
|---|---|---|---|---|---|
Amgen Inc.AMGN Office of Assistant Secretary for Preparedness and Response THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF ROMIPLOSTIM FOR TREATMENT OF HEMATOPOIETIC SUBSYNDROME-ACUTE RADIATION SYNDROME (HS-ARS) AND CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT) AND A DRUG DELIVERY DEVICE FEASIBILITY PROJECT WITH AN OPTION TO | 政府合同 进行中 置信度 98% | $26.4M — | A · 官方确认 |
结构化政府合同或两端官方记录；金额与合同编号可回到原始记录核验。
SEC、公司 IR 或 EIA 正式材料点名对手方、项目或设施；方向不明确时单独标注。
海关、提单等物流信号只能作为线索，不单独写成已确认供销事实。
| 2026-07-30 |
| 核验证据 |
Amgen Inc.AMGN Office of Assistant Secretary for Preparedness and Response NPLATE ADMINISTRATION KIT DEVELOPMENT FOR THE TREATMENT OF APPROVED INDICATIONS, INCLUDING ACUTE RADIATION SYNDROME (ARS) | 政府合同 进行中 置信度 98% | $7.3M — | A · 官方确认 AMGEN INC. received a federal award currently valued at $7,290,924 from Office of Assistant Secretary for Preparedness and Response. NPLATE ADMINISTRATION KIT DEVELOPMENT FOR THE TREATMENT OF APPROVED INDICATIONS, INCLUDING ACUTE RADIATION SYNDROME (ARS) USAspending.gov | 2026-07-30 | 核验证据 |